{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-226751","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2026-05-15T20:13:34+00:00","discovered_at":"2026-05-15T20:19:00.265641+00:00","generated_at":"2026-05-15T20:19:21.408226+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Candel reports 39% improvement in prostate cancer-specific DFS with aglatimagene in phase 3 extended follow-up","bullets":["Prostate cancer-specific DFS improved 39% vs placebo (HR 0.61, p=0.0031) at median 58-month follow-up.","Consistent favorable trends in TTBF, TTM, metastasis rate, and TTNT in ITT population.","In intermediate-risk subgroup (85% of patients), 90% reduction in time to metastasis (HR 0.1).","Company plans to submit BLA to FDA in Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-226751","json":"https://secwatch.observer/filing/0001193125-26-226751.json","markdown":"https://secwatch.observer/filing/0001193125-26-226751.md","text":"https://secwatch.observer/filing/0001193125-26-226751.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000119312526226751/0001193125-26-226751-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000119312526226751/d106447d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T20:19:21.408226+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}